Timofibrate
Latest Information Update: 13 Jan 1995
At a glance
- Originator GlaxoSmithKline
- Class Antihyperlipidaemics; Fibric acid derivatives
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia